
Barxbuddy Reviews: Is This Anti Barking Device Worth Buying?
MIDDLESEX, United Kingdom, May 05, 2025 (GLOBE NEWSWIRE) — Barking is natural for dogs—but when it becomes excessive, it can quickly turn your home into a stressful battleground. Whether it's the mailman, a passing car, or the wind rustling leaves outside, some dogs just won't stop barking. For many pet owners, this constant noise leads to sleepless nights, strained relationships with neighbors, and rising frustration. If that sounds familiar, you are not alone—and BarxBuddy might be the simple solution you have been looking for.
BarxBuddy is a handheld ultrasonic training device that promises to stop barking and other unwanted behaviors with the push of a button. It is painless, easy to use, and designed to help dogs learn better behavior—without shock collars, harsh punishment, or expensive obedience classes. In fact, over 100,000 dog owners have already tried it and are sharing their stories online, calling BarxBuddy a game changer for their homes.
But does it really work? Or is it just another overhyped pet gadget?
In this in-depth BarxBuddy review, we will explore everything you need to know about the device—from how it works and who it's for, to what real users are saying and whether it's truly worth buying. If you are looking for a humane way to correct barking, jumping, chewing, or other disruptive behaviors, this guide will help you decide if BarxBuddy is the right fit for you and your dog.
Let's dive in.
What Is BarxBuddy Dog Trainer?
(Barxbuddy Reviews)
BarxBuddy is a compact, handheld ultrasonic training device designed to help dog owners manage excessive barking and unwanted behaviors—instantly and humanely. It works by emitting a high-frequency sound that only dogs can hear, grabbing their attention without causing pain, fear, or discomfort. The moment your dog begins barking or acting out, a quick press of the button interrupts the behavior, allowing you to redirect their focus and reinforce better habits.
Unlike shock collars or choke chains, BarxBuddy does not rely on physical punishment. Instead, it leverages ultrasonic sound—a proven training method supported by veterinarians and dog behaviorists—to encourage positive behavior in a gentle, stress-free way. The sound is completely safe for dogs and inaudible to humans, making it an ideal tool for homes, public walks, and even crowded areas.
What makes BarxBuddy trainer even more appealing is its versatility. It works across all breeds and sizes—from tiny Shih Tzus to large Rottweilers—and is effective both indoors and outdoors with a range of up to 33 feet (10 meters). Whether you're dealing with barking, jumping, digging, chewing, or aggression, BarxBuddy gives you a simple, one-click solution to regain control and restore peace at home.
With its sleek design, built-in flashlight for night walks, and long-lasting rechargeable battery, BarxBuddy dog trainer offers more than just behavior correction—it offers confidence, calm, and better communication between you and your dog.
DON'T MISS OUT: Barxbuddy Ultrasonic Device Is Available At A Special Price – Click Here To Order Directly From The Official Website
How Does BarxBuddy Work?
BarxBuddy works by using ultrasonic sound technology—a high-frequency noise that's inaudible to humans but instantly noticeable to dogs. When activated, the sound captures the dog's attention, interrupting barking or other unwanted behaviors like jumping, chewing, or digging. This redirection allows the owner to reinforce calm, obedient behavior without using force or causing fear.
The device features dual training modes:
• Ultrasonic only
• Ultrasonic + LED flashlight (useful for night walks and added distraction)
BarxBuddy operates at a range of up to 33 feet (10 meters), making it suitable for both indoor use and outdoor activities like walks or backyard training. Whether the trigger is a knock at the door or another dog across the street, BarxBuddy gives owners immediate control with just one click.
Importantly, the device is designed to be humane and safe. Unlike shock collars or choke chains, BarxBuddy does not rely on physical punishment. Instead, it engages the dog's natural sensitivity to sound in a way that's non-harmful and stress-free.
In just a few consistent uses, many dogs begin to understand that the sound signals a need to stop the behavior—making it an effective tool for fast, painless behavior correction.
Key Features of BarxBuddy Ultrasonic Device
(Barxbuddy Trainer Reviews)
BarxBuddy isn't just another dog gadget—it's a thoughtfully engineered training tool designed to give dog owners safe, fast, and reliable control over excessive barking and bad behavior. Here's a closer look at the standout features that make BarxBuddy a go-to solution for pet parents around the world:
1. One-Click Control
BarxBuddy is incredibly easy to use. With just a single press of a button, it emits an ultrasonic sound that immediately captures your dog's attention. There's no complicated setup or need for prior training knowledge. Whether you're inside the house or out on a walk, the quick response lets you take control of your dog's behavior in real time.
2. Multiple Ultrasonic Sound Modes
The device offers three ultrasonic frequency settings—continuous, intermittent, and cycling. This allows owners to fine-tune the response based on their dog's behavior and sensitivity. Some dogs respond better to pulsing sounds, while others react more effectively to a steady tone. BarxBuddy gives you the flexibility to adjust accordingly.
3. Dual Modes for Maximum Effectiveness
BarxBuddy doesn't rely on sound alone. The device includes two training modes:
• Ultrasonic-only mode for basic behavior correction
• Ultrasonic + LED flashlight mode for added visual distraction—ideal during walks, night use, or when facing an aggressive dog
This combination enhances the effectiveness of the training by engaging both the dog's hearing and visual focus.
4. Extended Control Range (Up to 33 Feet / 10 Meters)
Unlike many training tools that only work at close range, BarxBuddy operates at a distance of up to 33 feet, giving owners flexibility to intervene before behavior escalates. This is especially helpful during off-leash moments in the backyard, dog parks, or walks through busy areas.
5. Built-in LED Flashlight
The integrated flashlight is perfect for early morning or evening walks, helping you stay visible and in control. It also acts as an additional deterrent for unfamiliar or aggressive dogs encountered during outings.
6. Auto Shut-Off for Safety
To protect your dog's hearing and prevent overuse, BarxBuddy includes an automatic shut-off that kicks in after 10 seconds of continuous use. This ensures humane, controlled training and prevents accidental long exposure.
7. Long-Lasting Rechargeable Battery
A single 2-hour charge powers the device for up to 60 days, thanks to its 1200mAh rechargeable battery. There is no need to constantly replace batteries—saving you time and money.
8. Haptic Feedback for Confirmation
Each time you press the button; you will feel a subtle vibration that lets you know the device is working correctly. This is especially useful during walks or when using the flashlight mode in the dark.
9. Lightweight & Portable Design
Compact, lightweight, and pocket-sized, BarxBuddy is designed for convenience. Slip it into your pocket, attach it to a leash, or keep it by the door—it is always ready when you need it.
Together, these features make BarxBuddy not just a tool for stopping barking, but a reliable training companion that enhances communication, reinforces good habits, and restores calm in your home.
What Makes BarxBuddy Different from Shock or Choke Collars?
(Barx Buddy Reviews)
Unlike traditional training tools that rely on physical punishment, BarxBuddy offers a humane and effective alternative that does not hurt, scare, or confuse your dog. While shock collars and choke chains may interrupt bad behavior, they often do so through fear, discomfort, or pain—leading to anxiety, mistrust, and long-term behavioral problems.
BarxBuddy works differently.
It uses ultrasonic sound—completely safe and painless—to instantly capture your dog's attention and redirect their behavior. There's no need for yelling, yanking leashes, or sending electric jolts. It's a gentle, science-backed method that promotes better behavior without causing distress.
Shock collars require careful calibration, often involve trial and error, and can easily overstimulate or harm sensitive dogs. Choke collars, on the other hand, rely on physical force and can cause injury, especially in smaller breeds. Both methods are intimidating for many owners and uncomfortable for pets.
BarxBuddy, by contrast, is as simple as clicking a button. There are no straps, no wires, and no physical contact. It is lightweight, easy to carry, and works from up to 33 feet away—indoors or outdoors. It is also more inclusive, suitable for dogs of all sizes, ages, and temperaments.
Most importantly, BarxBuddy encourages calm, consistent training. You remain in control without needing to overpower or frighten your dog. That makes it not just safer, but more effective in building lasting good habits.
In short, BarxBuddy offers the same goal—behavior correction—without the fear, pain, or complexity of traditional tools. It is the smarter, kinder way to train.
DON'T MISS OUT: Barxbuddy Ultrasonic Device Is Available At A Special Price – Click Here To Order Directly From The Official Website
Who Is BarxBuddy Anti Barking Device For?
BarxBuddy is designed for any dog owner who wants to correct bad behavior in a safe, gentle, and effective way—without resorting to force or punishment. Whether you have a young pup just learning boundaries or an older dog with ingrained habits, BarxBuddy offers a practical training solution that fits seamlessly into daily life.
It is especially useful for owners dealing with:
• Excessive barking at visitors, cars, mail carriers, or even small noises
• Jumping on guests or strangers
• Chewing, digging, or destructive behavior around the house or yard
• Leash pulling or overreacting during walks
• Difficulty with commands or dogs that ignore call-backs
• Aggressive encounters with other dogs while outdoors
BarxBuddy is suitable for all dog breeds—large, medium, and small—and adapts well to various temperaments. It is also a great option for first-time pet owners who may not have experience with advanced training tools or obedience classes.
Because it relies on ultrasonic sound and positive reinforcement rather than harsh corrections, it's ideal for those who want to maintain trust and emotional connection with their dog throughout the training process.
Whether you're trying to manage indoor disruptions or regain control during outdoor walks, BarxBuddy helps you stay calm, focused, and in control—with just a simple click.
How to Use BarxBuddy (Step-by-Step Instructions)
One of the biggest advantages of BarxBuddy is how simple it is to use. You don't need any special training or experience. Just follow these three basic steps to begin correcting unwanted behavior and reinforcing positive habits:
Step 1: Train
When your dog starts barking excessively or displaying unwanted behavior (like jumping, chewing, or digging), simply press the BarxBuddy button. The ultrasonic sound will immediately catch your dog's attention and interrupt the behavior without causing pain or fear.
Step 2: Treat
Once your dog stops the behavior or redirects attention to you, reward them with praise, a treat, or affection. This positive reinforcement helps your dog associate good behavior with pleasant outcomes, making training more effective and consistent.
Step 3: Repeat
Use BarxBuddy consistently whenever the unwanted behavior occurs. Over time, your dog will begin to understand the cue, adjust their behavior, and respond to your direction more reliably—even without the device.
Consistency is key. BarxBuddy is most effective when paired with calm, positive training and regular use. It's not just about stopping bad habits—it's about teaching better ones in a humane and respectful way.
BarxBuddy Reviews Consumer Reports and Complaints
Thousands of dog owners across the United States, Canada, Australia and UK have shared their positive experiences with BarxBuddy, praising how quickly and effectively it helped transform their pet's behavior. From excessive barking to disobedience during walks, many users report noticeable improvements within days or weeks of consistent use.
Here's what some verified buyers are saying:
Jessica L. – Verified Purchase
'Finally, a solution that works! Our house is quiet again. I didn't think anything would calm our dog down, but BarxBuddy made a huge difference.'
Mark R. – Verified Purchase
'I haven't had to apologize to my neighbors in weeks. The barking has nearly stopped, and I'm actually enjoying walks again.'
Emily S. – Verified Purchase
'One click, instant results. This thing is magic. My dog immediately responded, and it's made life at home so much more peaceful.'
Michelle P. – Verified Purchase
'We can finally go for a walk without Benji barking his head off at everyone! It took about two weeks, but it was worth it. No obedience classes needed.'
Peter G. – Verified Purchase
'I have a large rottweiler that used to jump at people. I was skeptical, but the first time I used BarxBuddy, he stopped and sat down. It really works.'
Brenda M. – Verified Purchase
'During a night walk, an off-leash dog came at us. I pressed BarxBuddy, and it stopped immediately. It gave me peace of mind in a scary situation.'
These reviews reflect a common theme: BarxBuddy brings fast results without stress or punishment. From small breeds to large dogs, many owners credit this device with restoring peace and strengthening their connection with their pets.
MUST SEE: CLICK HERE NOW TO GET BARXBUDDY DIRECTLY FROM THE OFFICIAL WEBSITE AT A DISCOUNTED PRICE
Real Results in 3 Weeks: What to Expect with BarxBuddy
BarxBuddy has gained attention for its ability to reduce excessive barking and correct unwanted behaviors within just a few weeks of consistent use. While individual results may vary based on the dog's temperament and history, many owners have reported noticeable improvements within the first few days.
Week 1: Immediate Disruption of Barking
In the first week, the device can interrupt barking the moment it begins. The ultrasonic sound grabs the dog's attention without causing pain or distress. This pause creates an opportunity for the owner to redirect the dog's focus and reinforce calm behavior—often for the first time in challenging situations like door knocks, car sounds, or unfamiliar guests.
Week 2: Increased Responsiveness and Calmer Behavior
With repeated use, many dogs begin to associate the ultrasonic cue with redirection. By the second week, pet owners often observe fewer outbursts and improved behavior during walks, especially around other dogs or common triggers. Dogs may begin looking to their owners for direction rather than reacting instinctively.
Week 3: More Controlled Reactions and Better Communication
By the third week, dogs typically show a clear change in behavior. Barking becomes less frequent, and dogs tend to pause and wait for cues before reacting. Owners report a calmer household environment and improved communication with their pets, making everyday life more manageable and less stressful.
BarxBuddy does not promise overnight results, but with consistent use and positive reinforcement, it helps foster long-term behavior improvements in a humane and effective way.
Is BarxBuddy a Scam or Legit?
BarxBuddy is a legitimate dog training tool backed by thousands of verified purchases, expert endorsements, and a large base of satisfied customers. It's not a gimmick or a generic product—it's a specifically designed ultrasonic device engineered to safely address common dog behavior problems like barking, jumping, and leash pulling.
Several signs point to BarxBuddy's legitimacy: Verified Customer Reviews: Real dog owners consistently report positive results, with many noticing improvements within days or weeks of use.
Transparent Company Policies: BarxBuddy is sold through an official website that offers secure checkout, a 30-day money-back guarantee, and fast, trackable U.S. shipping.
Safe and Humane Design: The technology uses ultrasonic frequencies—recognized by trainers and vets as a gentle alternative to shock-based methods.
High Demand and Low Inventory Warnings: Limited availability in some regions indicates strong customer interest and sales volume—not the behavior of a fraudulent product.
While there are imitation products on third-party platforms, purchasing directly from the official site ensures you are getting the real device with full warranty protection and support.
In short, BarxBuddy is not a scam. It is a legitimate, well-reviewed solution for dog training that delivers on its promises when used correctly and consistently.
DON'T MISS OUT: Barxbuddy Device Is Available At A Discounted Price – Click Here To Order Directly From The Official Website
Pros and Cons of Barx Buddy Ultrasonic Device
Like any training tool, BarxBuddy has its strengths and limitations. Here is a balanced look at the key advantages and potential drawbacks, based strictly on user experiences and product features highlighted in the official resources:
Pros (Barxbuddy Trainer Reviews) Instant Behavior Disruption : Stops barking, jumping, and other bad behaviors with a single click.
: Stops barking, jumping, and other bad behaviors with a single click. 100% Pain-Free and Humane : Uses ultrasonic sound—not shock or choke—to correct behavior safely.
: Uses ultrasonic sound—not shock or choke—to correct behavior safely. Works Across All Dog Breeds : Effective for small, medium, and large dogs.
: Effective for small, medium, and large dogs. Long Range (Up to 33 Feet): Useful indoors and outdoors, including walks and public settings.
Useful indoors and outdoors, including walks and public settings. Built-in LED Flashlight : Ideal for night walks or deterring unfamiliar dogs in dark environments.
: Ideal for night walks or deterring unfamiliar dogs in dark environments. Rechargeable with Extended Battery Life : Just a 2-hour charge delivers up to 60 days of use.
: Just a 2-hour charge delivers up to 60 days of use. Compact and Easy to Carry : Lightweight design fits easily in a pocket, bag, or on a leash.
: Lightweight design fits easily in a pocket, bag, or on a leash. No-Hassle 30-Day Returns: Full refund if not satisfied—no risk involved.
Cons (Barxbuddy Reviews) Not All Dogs Respond the Same Way : While effective for many, results may vary depending on the dog's temperament or hearing ability.
: While effective for many, results may vary depending on the dog's temperament or hearing ability. Requires Consistent Use : BarxBuddy is a training aid, not a one-time fix. Behavior correction takes repetition and positive reinforcement.
: BarxBuddy is a training aid, not a one-time fix. Behavior correction takes repetition and positive reinforcement. Ultrasonic Sound May Not Work in Loud Environments: The effectiveness may be reduced in very noisy or chaotic areas.
Overall, the pros clearly outweigh the cons for most users, especially those seeking a gentle and simple way to train their dogs without fear or pain.
BarxBuddy Price – What Is the Cost?
BarxBuddy is currently available at a massive 60% discount, with additional savings on bundle purchases. The more you buy, the more you save—making it ideal for multi-pet households or for gifting to fellow dog owners.
Here is the current pricing breakdown:
Perfect for single-dog homes. Selling out fast.
Best for households with more than one dog or as a backup unit.
Top value. Includes 10% extra discount on top of the sale.
Best deal for families, breeders, or those gifting to others.
Each purchase includes the official ultrasonic device and is eligible for the 30-day money-back guarantee. No hidden charges, and all payments are processed through a secure and encrypted checkout on the official BarxBuddy site.
Where to Buy BarxBuddy
BarxBuddy is currently available through a limited-time offer on its official website , where buyers can secure up to 50% off. This exclusive flash sale is part of a promotion that may not be available elsewhere—and stock is reportedly running low in several locations, including United States and Canada.
Purchasing from the official source offers several key benefits: Guaranteed Authenticity – You will receive the genuine BarxBuddy device with all its built-in features and high-quality construction.
– You will receive the genuine BarxBuddy device with all its built-in features and high-quality construction. Limited-Time Discounts – Get 50% off before the offer ends or inventory runs out.
– Get 50% off before the offer ends or inventory runs out. Fast U.S. Shipping – Orders are fulfilled quickly, minimizing the wait time.
– Orders are fulfilled quickly, minimizing the wait time. Risk-Free Purchase – A 30-day money-back guarantee ensures you can try it out without worry.
– A 30-day money-back guarantee ensures you can try it out without worry. Secure Checkout – The payment process is encrypted and fully protected.
If you want a safe, effective, and humane way to train your dog—without delay—it's best to act fast while the current discount is still active.
CLICK HERE NOW TO BUY BARXBUDDY DIRECTLY FROM THE OFFICIAL WEBSITE AT A DISCOUNTED PRICE
Frequently Asked Questions (Barxbuddy Reviews)
1. How does BarxBuddy stop my dog's barking?
BarxBuddy emits a high-frequency ultrasonic sound that only dogs can hear. The sound instantly interrupts barking or other unwanted behavior, allowing you to redirect your dog's attention and reinforce positive habits.
2. Does it hurt my dog's ears?
No. The ultrasonic sound is completely safe and does not cause pain or harm. It's designed to be a humane and non-aggressive training method that grabs your dog's attention without fear or discomfort.
3. Can I use it on other dogs?
Yes. BarxBuddy can be used on other dogs, whether at home, during walks, or at the park. It works on dogs of all sizes and breeds as long as they can hear ultrasonic frequencies.
4. What unwanted behaviors does BarxBuddy work for?
BarxBuddy is effective for more than just barking. It can help manage jumping, digging, chewing, leash pulling, and aggression. It works best when combined with consistent reinforcement and training.
5. How quickly will I see results?
Some dogs respond immediately, while others may take a few days to a couple of weeks. Consistency and positive reinforcement are key to seeing lasting behavior changes.
6. What is the working range of BarxBuddy?
The device is effective up to 33 feet (10 meters), making it suitable for indoor and outdoor use. This range allows you to stay in control even from a distance.
7. Do I have to buy batteries for BarxBuddy?
No. BarxBuddy features a built-in rechargeable battery. A full 2-hour charge provides up to 60 days of use, eliminating the need to constantly replace batteries.
8. What if BarxBuddy doesn't work for my dog?
While most dogs respond well, every pet is different. If you don't see results, you can return the device within 30 days for a refund, thanks to the no-hassle money-back guarantee.
9. What comes in the packaging?
Each BarxBuddy package includes the ultrasonic device, a USB charging cable, and a quick-start guide with instructions on proper use and best training practices.
Final Verdict: Is BarxBuddy Worth It?
BarxBuddy offers a humane, effective, and easy-to-use solution for dog owners struggling with barking and other disruptive behaviors. It replaces outdated tools like shock collars and choke chains with a simple, non-invasive approach that prioritizes safety and long-term behavioral improvement.
With just one click, the ultrasonic sound interrupts bad habits and redirects your dog's attention—without causing harm, fear, or confusion. For many users, this small device has made a big difference in restoring calm at home, making walks more enjoyable, and strengthening the bond between pet and owner.
The combination of smart features—like long-range functionality, rechargeable battery, built-in flashlight, and multi-mode operation—makes BarxBuddy a versatile training tool that adapts to a variety of dogs and situations.
Backed by thousands of positive reviews and a 30-day money-back guarantee, BarxBuddy stands out as a reliable option for anyone looking to regain control and promote better behavior—without stress or punishment.
If you are tired of constant barking and chaos, and you want a fast, gentle, and proven solution, BarxBuddy is well worth considering—especially while the 50% off offer is still available.
CLICK HERE NOW TO GET BARXBUDDY ULTRASONIC DEVICE DIRECTLY FROM THE OFFICIAL WEBSITE AT A DISCOUNTED PRICE
Email: [email protected]
Legal Disclaimer : This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/3f5be5c5-99ac-49c9-8832-5d14d978c1e0
https://www.globenewswire.com/NewsRoom/AttachmentNg/4ecde2f4-171a-413e-9831-bde98ea0f74b
https://www.globenewswire.com/NewsRoom/AttachmentNg/c056e059-6c0c-42d1-b309-19200bc7ef5a
https://www.globenewswire.com/NewsRoom/AttachmentNg/5c3813e6-3b6f-453c-bb2e-9f619c5722e5
https://www.globenewswire.com/NewsRoom/AttachmentNg/a9aa7d9d-eb3e-4b5f-b864-b97444e65e86
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
BonDo Seeks 100K USD Investments to Launch Innovative Brain Boosting Soup Brand by Year End
BonDo, a part of Për Brand Solutions, is seeking funding to accelerate its healthy soup product to market at a commercial scale. Atlanta, Georgia, June 11, 2025 (GLOBE NEWSWIRE) -- BonDo BonDo, a pioneering nutrition startup founded by brain science researcher Era Kovanxhi, is officially opening the door to investment opportunities as it seeks to raise $100,000 to bring its innovative 'stir-in' soup product to market. Backed by years of academic research and inspired by Kovanxhi's personal health journey, BonDo is on a mission to make nutrient-dense meals accessible and functional, offering investors both profit and purpose. 'BonDo was born from my personal struggles as a student, balancing academic rigor with skin health, energy crashes, and a demanding schedule,' says Kovanxhi, a scientist currently pursuing a PhD in Brain Science and Education. 'I started experimenting with vitamin combinations to help my body and brain perform better. When I saw the difference in myself and my family, I knew I had something meaningful to share.' Created as a solution for busy individuals in need of fast, nutrient-rich meals, BonDo's stir-in soup flavor bits combine ease of use with cutting-edge nutrition. Simply add water for a complete, flavorful soup that supports brain health, energy, skin health, calcium retention, and anti-aging benefits. BodDo VarietiesWith varieties such as BonDo Butter Bits, BonDo Leftovers, and BonDo Soup Booster Bits, each Bit has unique combinations of flavorful nodes of herbs, garlic, lemon, avocado, etc. For the ones with a sweet tooth and love for caffeine, it offers BonDo Coffee Milk Variety Bits, BonDo Coffee Flavor Booster Bits, and BonDo Oatmeal, with flavorful nodes from coffee, almond, hazelnut, and apple crisps, to name a few. The BonDo Baby variety contains healthy nutrients of wheat berry, butternut, chamomile, avocado, pumpkin, and vegetables. Part of Për Brand Solutions, this research-based initiative was developed to merge science-driven wellness with community-focused accessibility. Each BonDo mix includes core ingredients like chia seeds, rice, or dairy, naturally rich in Omega 3, Vitamin D & E, and calcium, nutrients that aid in everything from bone strength to cognitive clarity. These nutrient combinations are also being explored in Kovanxhi's current work on Klotho protein, a molecule linked to anti-aging, calcium retention, and blood sugar regulation. BonDo - How To UseAlready tested through small-batch, homemade orders, BonDo is now ready to scale production with the help of aligned investors. The funding will go toward manufacturing, packaging, continuous product refinement, expansion of flavor options, marketing, brand development, and the launch of sales operations ahead of the 2025 holiday season. Investors will receive a percentage of profits, making this both a high-potential business venture and a socially driven opportunity. 'BonDo is more than food. It's a response to the overwhelming demand for convenience without compromising wellness,' says Kovanxhi. 'This is created for people like myself and my community, those low on time and budget, but who still deserve high-quality, nourishing meals.' Media Contact Name: Era Kovanxhi Email: There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any security or any other product or service in this article. Moreover, nothing contained in this should be construed as a recommendation to buy, sell, or hold any investment or security, or to engage in any investment strategy or transaction. It is your responsibility to determine whether any investment, investment strategy, security, or related transaction is appropriate for you based on your investment objectives, financial circumstances, and risk tolerance. Consult your business advisor, attorney, or tax advisor regarding your specific business, legal, or tax in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. 'It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon,' said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or follow us on Twitter. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contact:Pete Rahmerprahmer@ Media:Dan Budwick1AB973-271-6085dan@
Yahoo
4 hours ago
- Yahoo
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 months Acceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosing Data support further dose optimization to maximize therapeutic benefit of MP0533, with dosing in cohort 9 now ongoing ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announced a poster presentation with positive, updated data from a Phase 1/2a trial of the tetraspecific T-cell engager MP0533 in relapsed/refractory acute myeloid leukemia (AML), at the 30th EHA (European Hematology Association) Congress, taking place in Milan on June 12–15, 2025. The poster, Updated Results from the Ongoing Phase 1/2a Study of MP0533, a Tetra-Specific Designed Ankyrin Repeat Protein (DARPin; CD33 x CD123 x CD70 x CD3), in Patients with Relapsed/Refractory AML or MDS/AML, outlines the impact of accelerated step-up dosing regimen (steeper and faster) of MP0533 on exposure and clinical responses in cohort 8, providing the rationale for further optimization to the dosing regimen implemented in the ongoing cohort 9. Data from cohort 8 show that 3 of 8 evaluable patients (> 30%) achieved a clinical response after the first cycle, with one patient achieving a complete response and two patients a complete response with partial hematologic recovery as best overall response. Two patients maintained a response for more than 3 months and one patient remains on treatment, maintaining a response beyond 6 months at the time of data cutoff (14 April 2025). Cohort 8 implemented a higher starting dose than cohorts 1-7, and the inclusion of an additional day of dosing, reaching the target dose by day 12, as opposed to day 15 previously. Cohort 8 data indicate that patients maintained exposure to MP0533 for a longer period of time within the predicted therapeutic range through the accelerated step-up dosing scheme, within the first cycle. Data show that patients reached over 4 days of relevant exposure, with 5 out of 8 patients displaying > 50% blast reduction. MP0533 shows an acceptable safety profile after adjustment of the target dose in cohort 8. 'I am encouraged by the number and level of responses observed in the most recent cohort and have started to include patients with the new 'dense administration' schedule aiming to establish the full potential of this product for our R/R AML patients,' said Pierre Bories, MD, PhD, Principal Investigator at Institut Universitaire du Cancer Toulouse - Oncopole, France. In cohorts 1-7, where step-up dosing reached target dose by day 15, exposure to predicted therapeutic doses was limited to roughly 2 days in the first cycle, most likely due to target-mediated-drug deposition. This prior treatment protocol, despite demonstrating initial blast reductions in ~30% of patients, resulted in limited responses. Based on the encouraging antitumor activity observed in cohort 8, the amended protocol for cohort 9 and beyond includes further acceleration of the step-up dosing to reach therapeutically-relevant doses faster, increased frequency of dosing for higher cumulative MP0533 exposure, and the introduction of anti-CD20 premedication to mitigate loss of exposure, with the objective to further increase the depth and duration of responses in patients. Cohort 9 is currently dosing patients and initial data from the amended dosing scheme are expected in H2 2025. Additionally, future study cohorts will evaluate the combination of azacitidine/venetoclax with MP0533. Details of the presentation: Updated Results from the Ongoing Phase 1/2a Study of MP0533, a Tetra-SpecificDesigned Ankyrin Repeat Protein (DARPin; CD33 x CD123 x CD70 x CD3), in Patients withRelapsed/Refractory AML or MDS/AMLTime: June 13, 18:30 - 19:30 CEST (Poster Session 1) About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact:Seth Lewis, SVP Investor Relations & StrategyConcord, Massachusetts, +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Tel: +41 44 575 19 35 Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as 'aim', "anticipate', 'expect', 'guidance', 'intend', 'outlook', 'plan', 'potential', 'will' and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data